Around 10% of Deaths from Coronary Stenting, Balloon Angioplasty Are Preventable | Complications During Procedures Only Contributed to Death in About 20% of Cases

Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally invasive procedure to unclog the arteries that feed the heart.

While PCI, which includes both angioplasty and stenting, is one of the most common operations in the world, it does carry a small (about 1-2%) but significant risk of death. Around 10% of all deaths following percutaneous coronary intervention are potentially preventable, a study led by Michigan Medicine finds.

The results are published in PLOS ONE.

“Deaths in the hospital after PCI are rare and mostly occur in patients who arrive after a heart attack, especially if their cases involve shock,” said senior author Hitinder Gurm, M.B.B.S., chief medical officer at University of Michigan Health and medical director of the Blue Cross Blue Shield of Michigan Cardiovascular Consortium, or BMC2.

“The vast majority of deaths after PCI are unpreventable and related to patients’ underlying conditions for which they are undergoing the procedure. This is a stark change from the 1990s when the majority of deaths were traceable to procedural complications.”

The research team analyzed deaths after PCI occurring at 39 Michigan hospitals participating in BMC2 between 2012 and 2014. These hospitals use procedural and outcome data to inform quality projects to improve care and patient outcomes.

Procedural complications contributed to 20% of the nearly 1,200 deaths reported during the study period. Just over one quarter of the patients who died were considered low risk, meaning a PCI-related mortality risk score estimated they had a 95% or greater chance of survival.

Of the deaths that were considered preventable, 10.1% in total, angioplasty and stenting was deemed to be of low value and potentially avoidable nearly one third of the time.

Researchers say the data suggests a need to focus on optimizing appropriateness of PCI to ensure providers are limiting rare, preventable deaths from this common procedure.

“Our data may help inform how cath labs conduct morbidity and mortality conferences, a common quality improvement practice at many hospitals, by focusing on patients with low predicted risk of mortality who subsequently experienced an adverse event,” said first author Francesco Moroni, M.D., fellow at the Robert M. Berne Cardiovascular Research Center at University of Virginia.

“Such a focus may be an effective method of identifying on periprocedural practices, as opposed to patient-related factors, that may have played a role in a patient’s adverse outcome.”

Additional Authors

Include Milan Seth, M.Sc., of University of Michigan, Francesco Moroni, M.D., of University of Virigina and Università Milano-Bicocca, Hameem U. Changezi, M.D., of McLaren Flint Cardiology, Milind Karve, M.D., of Sparrow Health, Dilip S. Arora, M.D., of Corewell Health South Lakeland, Manoj Sharma, M.D., M.B.A., of Covenant HealthCare, Elizabth Pielsticker, M.D., of Henry Ford-Jackson, Aaron D. Berman, M.D., of Corewell Health William Beaumont University Hospital, Daniel Lee, M.D., of McLaren Bay Heart and Vascular, M. Imran Qureshi, M.D., of DMC Sinai Grace Hospital, and Lorenzo Azzalini, M.D., Ph.D., M.Sc., of Unversity of Washington.

Funding

Support for BMC2 is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.

Disclosure

Although Blue Cross Blue Shield of Michigan and BMC2 work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

Citation: “Cause and preventability of in-hospital mortality after PCI: a statewide root-cause analysis of 1,163 deaths,” PLOS ONE. DOI: 10.1371/journal.pone.0297596

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.